Neutropenia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 118 pages | ID: N4632844B5CCEN
VPAResearch

Abstracts

2020 Neutropenia PIPELINE HIGHLIGHTS
Neutropenia is one of the widely researched conditions during 2020 with 24 companies actively focusing on realizing pipeline’s potential. Development of Neutropenia medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Neutropenia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Neutropenia.

Good progress is anticipated during 2020 and 2021 with Neutropenia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Neutropenia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Neutropenia DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Neutropenia pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Neutropenia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Neutropenia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Neutropenia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Neutropenia DRUG PROFILES
Neutropenia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Neutropenia COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Neutropenia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Neutropenia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 24 Neutropenia companies including company overview, key snapshot, contact information, and their strategies on accelerating Neutropenia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Apotex Inc, BeyondSpring Inc, Biocon Ltd, Biocure Technology Inc, Biosidus SA, Bolder BioTechnology, Cellerant Therapeutics Inc, Chong Kun Dang Pharmaceutical Corp, Cleveland BioLabs Inc, CPL Biologicals Pvt Ltd, Dr. Reddy's Laboratories Ltd, Emendo Biotherapeutics, Enzychem Lifesciences Corp, Kashiv BioSciences, Lupin Ltd, Merck & Co Inc, Mycenax Biotech Inc, Nexgen Biosciences, Phoenicia Biosciences Inc, Prolong Pharmaceuticals LLC, Siam Bioscience Co Ltd, Toko Pharmaceutical Industries Co Ltd, USV Pvt Ltd, X4 Pharmaceuticals Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Neutropenia
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO NEUTROPENIA

1.1 Neutropenia- Disease overview
1.2 Neutropenia- Market Size
1.3 Neutropenia- Companies Involved

2. NEUTROPENIA PIPELINE SNAPSHOT- 2020

2.1 Neutropenia Pipeline by Phase
2.2 Neutropenia Pipeline by Mechanism of Action
2.3 Neutropenia Pipeline by Route of Administration
2.4 Neutropenia Pipeline- New Molecular Entities
2.5 Neutropenia Pipeline- Orphan Drug Designation/ Special Designation

3. NEUTROPENIA DRUG PROFILES

3.1 Current Status
3.2 Neutropenia Drug Snapshot
3.3 Neutropenia Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Apotex Inc Neutropenia Pipeline Insights and Clinical Trials
4.2 BeyondSpring Inc Neutropenia Pipeline Insights and Clinical Trials
4.3 Biocon Ltd Neutropenia Pipeline Insights and Clinical Trials
4.4 Biocure Technology Inc Neutropenia Pipeline Insights and Clinical Trials
4.5 Biosidus SA Neutropenia Pipeline Insights and Clinical Trials
4.6 Bolder BioTechnology Neutropenia Pipeline Insights and Clinical Trials
4.7 Cellerant Therapeutics Inc Neutropenia Pipeline Insights and Clinical Trials
4.8 Chong Kun Dang Pharmaceutical Corp Neutropenia Pipeline Insights and Clinical Trials
4.9 Cleveland BioLabs Inc Neutropenia Pipeline Insights and Clinical Trials
4.10 CPL Biologicals Pvt Ltd Neutropenia Pipeline Insights and Clinical Trials
4.11 Dr. Reddy's Laboratories Ltd Neutropenia Pipeline Insights and Clinical Trials
4.12 Emendo Biotherapeutics Neutropenia Pipeline Insights and Clinical Trials
4.13 Enzychem Lifesciences Corp Neutropenia Pipeline Insights and Clinical Trials
4.14 Kashiv BioSciences Neutropenia Pipeline Insights and Clinical Trials
4.15 Lupin Ltd Neutropenia Pipeline Insights and Clinical Trials
4.16 Merck & Co Inc Neutropenia Pipeline Insights and Clinical Trials
4.17 Mycenax Biotech Inc Neutropenia Pipeline Insights and Clinical Trials
4.18 Nexgen Biosciences Neutropenia Pipeline Insights and Clinical Trials
4.19 Phoenicia Biosciences Inc Neutropenia Pipeline Insights and Clinical Trials
4.20 Prolong Pharmaceuticals LLC Neutropenia Pipeline Insights and Clinical Trials
4.21 Siam Bioscience Co Ltd Neutropenia Pipeline Insights and Clinical Trials
4.22 Toko Pharmaceutical Industries Co Ltd Neutropenia Pipeline Insights and Clinical Trials
4.23 USV Pvt Ltd Neutropenia Pipeline Insights and Clinical Trials
4.24 X4 Pharmaceuticals Inc Neutropenia Pipeline Insights and Clinical Trials

5. NEUTROPENIA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information